

(D)

PRINTER RUSH ●

(PTO ASSISTANCE)

Application : 09/822,379 Examiner : K. CANELA GAU : 1642

From: L. MITCHELL Location: IDC FMF FDC Date: 7/25/05

Tracking #: 4113696 Week Date: 6/16/05

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	<u>3/30/01</u>	
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input type="checkbox"/> SPEC		

(X)

[RUSH] MESSAGE: ATTENTION CHIEF DRAFTS PERSON

FIG 2 + 3 ARE DARK.

THANK YOU
RSM

[XRUSH] RESPONSE: Drawings attached mailed

Drawings attached - 08/22/05

REHANTANG ABANTANG

INITIALS: ML

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER 09/822379	FILING/RECEIPT DATE 03/30/2001	FIRST NAMES APPLICANT LOW, PHILIP STEWART	ATTORNEY DOCKET NUMBER 3220-67883
--	--	---	---

BARNES & THORNBURG
11 SOUTH MERIDIAN
INDIANAPOLIS IN 46204

Examiner
CANELLA, KAREN

Art Unit
1642

Paper Number

Date Mailed: 08-05-05

Notice Regarding Drawings

Corrected drawings for the above-identified application, received in the USPTO on 03/30/2001 are still not acceptable for the reason(s) identified on the attached PTO-948. Applicant is given one opportunity to correct the informalities within a two-month time period from the mailing date of this Notice. **THIS TIME PERIOD IS NOT EXTENDABLE UNDER EITHER 37 CFR 1.136(a) OR 1.136(b).** Failure to take corrective action within the set period will result in abandonment of the application.

ATTACHMENT: PTO-948 Notice of Draftsperson's Patent Review

Martang

RETURN CORRECTED DRAWINGS TO:
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*Drawings received -
08/22/05 Approved -
Martang*

NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) filed (insert date) 03/30/01 are:

- A. approved by the Draftsperson under 37 CFR 1.84 or 1.152.
B. objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. Corrected drawings are required.

<p>1. DRAWINGS. 37 CFR 1.84(a): Acceptable categories of drawings: Black ink or Color (3 sets required).</p> <p><input type="checkbox"/> Color drawings are not acceptable until petition is granted. Fig(s) _____</p> <p><input type="checkbox"/> Pencil and non black ink not permitted. Fig(s) _____</p>	<p>8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i)</p> <p><input type="checkbox"/> Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) _____</p>
<p>2. PHOTOGRAPHS. 37 CFR 1.84(b)</p> <p><input type="checkbox"/> One (1) full-tone set is required. Fig(s) _____</p> <p><input type="checkbox"/> Photographs may not be mounted. 37 CFR 1.84(e)</p> <p><input type="checkbox"/> Photographs must meet paper size requirements of 37 CFR 1.84(f). Fig(s) _____</p> <p><input type="checkbox"/> Poor quality (half-tone). Fig(s) _____</p>	<p>9. SCALE. 37 CFR 1.84(k)</p> <p><input type="checkbox"/> Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction. Fig(s) _____</p>
<p>3. TYPE OF PAPER. 37 CFR 1.84(e)</p> <p><input type="checkbox"/> Paper not flexible, strong, white, and durable. Fig(s) _____</p> <p><input checked="" type="checkbox"/> Erasures, alterations, overwritings, interlineations, folds, copy machine marks not accepted. Fig(s) <u>1-17</u></p>	<p>10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l)</p> <p><input checked="" type="checkbox"/> Lines, numbers & letters not uniformly thick and well defined, clean, durable, and black (poor line quality). Fig(s) <u>2,3</u></p>
<p>4. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes:</p> <p><input type="checkbox"/> 21.0 cm by 29.7 cm (DIN size A4) or 21.6 cm by 27.9 cm (8 1/2x 11 inches)</p> <p><input type="checkbox"/> All drawing sheets not the same size.</p> <p><input type="checkbox"/> Sheet(s) _____</p> <p><input type="checkbox"/> Drawings sheets not an acceptable size. Fig(s) _____</p>	<p>11. SHADING. 37 CFR 1.84(m)</p> <p><input type="checkbox"/> Solid black areas pale. Fig(s) _____</p> <p><input type="checkbox"/> Solid black shading not permitted. Fig(s) <u>2,3</u></p>
<p>5. MARGINS. 37 CFR 1.84(g): Acceptable margins: Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm</p> <p><input checked="" type="checkbox"/> Margins not acceptable. Fig(s) <u>2,3</u></p>	<p>12. NUMBERS, LETTERS, & REFERENCE CHARACTERS. 37 CFR 1.84(p)</p> <p><input checked="" type="checkbox"/> Numbers and reference characters not plain and legible. Fig(s) <u>2,3</u></p> <p><input checked="" type="checkbox"/> Figure legends are poor. Fig(s) <u>2,3</u></p> <p><input type="checkbox"/> Numbers and reference characters not oriented in the same direction as the view. 37 CFR 1.84(p)(1) Fig(s) _____</p> <p><input type="checkbox"/> English alphabet not used. 37 CFR 1.84(p)(2) Fig(s) _____</p> <p><input checked="" type="checkbox"/> Numbers, letters and reference characters must be at least 32 cm (1/8 inch) in height. 37 CFR 1.84(p)(3). Fig(s) <u>2,3,1,4-17</u></p>
<p>6. VIEWS. 37 CFR 1.84(h)</p> <p>REMINDER: Specification may require revision to correspond to drawing changes, e.g., if Fig. 1 is changed to Fig. 1A, Fig 1B, and Fig. 1C, etc., the specification, at the Brief Description of the Drawings, must likewise be changed.</p> <p><input type="checkbox"/> Views not labeled separately or properly. Fig(s) _____</p>	<p>13. LEAD LINES. 37 CFR 1.84(q)</p> <p><input type="checkbox"/> Lead lines missing. Fig(s) _____</p>
<p>7. SECTIONAL VIEWS. 37 CFR 1.84(h)(3)</p> <p><input type="checkbox"/> Sectional designation should be noted with Arabic or Roman numbers. Fig(s) _____</p>	<p>14. NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1.84(n)</p> <p><input type="checkbox"/> Sheets not numbered consecutively, and in Arabic numbers beginning with number 1. Sheet(s) _____</p>
	<p>15. NUMBERING OF VIEWS. 37 CFR 1.84(u)</p> <p><input type="checkbox"/> Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) _____</p>
	<p>16. DESIGN DRAWINGS. 37 CFR 1.152</p> <p><input type="checkbox"/> Surface shading shown not appropriate. Fig(s) _____</p> <p><input type="checkbox"/> Solid black surface shading is not permitted except when used to represent the color black as well as color contrast. Fig(s) _____</p>

COMMENTS:

Fig. Labels placed incorrectly - Fig. 2,3,9-17

Reviewer Tang

If you have questions, call (703) 305-0333 x132

Date 08/05/05

Attachment to Paper No. _____

Drawings Received -

08/22/05

Approved Mhan Tang

EFFECT OF FOLATE TARGETED IMMUNOTHERAPY ON THE
SURVIVAL OF MICE WITH LUNG TUMOR IMPLANTS




FIG 1

09822379

24JK-FBP TUMOR IMAGING



PHASE CONTRAST
TUMOR (40X)

FIG. 2a



PHASE CONTRAST
KIDNEY (40X)

FIG. 2d




PHASE CONTRAST
LIVER (60X)

FIG. 2c



FITC FLUORESCENCE
TUMOR (40X)

FIG. 2e




FITC FLUORESCENCE
TUMOR (40X)



FITC FLUORESCENCE
LIVER (60X)



FITC FLUORESCENCE
MUSCLE (40X)




FITC FLUORESCENCE
MUSCLE (40X)

FIG. 2b

FIG. 2f


FIG. 2g

09822379




UNTREATED TRANSMITTED

FIG. 3c




FOLATE-FITC TREATED
TRANSMITTED

FIG. 3f



UNTREATED PE IMAGE

FIG. 3c




FOLATE-FITC TREATED
PE IMAGE

FIG. 3d



UNTREATED FITC IMAGE


FIG. 3a




FOLATE-FITC TREATED
FITC IMAGE

FIG. 3b


09822379



09822379



09822379



SYNERGISTIC EFFECT OF FEFITC AND IL-2
IN FOLATE-TARGETED IMMUNOTHERAPY





FIG. 7

09822379


THE EFFECT OF MOUSE NK CELL DEPLETION
ON FOLATE-TARGETED IMMUNOTHERAPY



TFII6.8

FIG. 9


DEVELOPMENT OF CELLULAR IMMUNITY
AGAINST THE PARENTAL M109 TUMOR CELLS




-○- PBS CONTROL GROUPS AT RESPECTIVE TUMOR IMPLANTATION TIME POINTS

-●-▲-▼-◆- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/DAY), AND IFN- α (25,000 U/DAY)

09822379




09822379



FITC. #1

09822379



09822379

THE EFFECT OF A THIRD CYTOKINE, GM-CSF ON
FOLATE-TARGETED IMMUNOTHERAPY






FIG 13

DAYS POST TUMOR IMPLANTATION

09822379



09822379



09822379

SYNERGISTIC EFFECT OF FEFITC AND IFN- α
AGAINST INTRAPERITONEAL M109 TUMOR




FIG 16

09822379

FOLATE-DNP FURTHER ENHANCED THE THERAPEUTIC EFFECT OF
A HIGH DOSE COMBINATION OF IL-2 AND IFN- α IN MICE
WITH PREEXISTING ANTI-DNP ANTIBODY




FIG 6. 17